BTA Holders,
The D225G genetic variation is increasingly seen as a major virulence factor in human Influenza strains. It works by enabling virus to attach to cells lining the lung rather than the upper respiratory tract.
Lung damage is what puts previously healthy individuals in intensive care on life support.
International trials on efficacy of intravenous "Relenza" (developed by Biota) are in progress. Some reports indicate "miraculous" recovery in critically ill patients.
With Tamiflu resistant strains there is no alternative antiviral to "Relenza" available. There are as yet no reports of long acting "Lani" antiviral (also developed by Biota) being used to treat critically ill influenza patients.
"Relenza" is a life-saver.
Regards
Kangaroo1
- Forums
- ASX - By Stock
- BTA
- tamiflu resistance spreads
tamiflu resistance spreads, page-6
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online